Technology
Health
Biotechnology

Merus

$12.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-0.39%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Merus and other stocks, options, ETFs, and crypto commission-free!

About

Merus N.V. Common Shares, also called Merus, is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Read More Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Employees
69
Headquarters
Utrecht, Utrecht
Founded
2003
Market Cap
291.91M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
42.18K
High Today
$12.85
Low Today
$12.62
Open Price
$12.85
Volume
1.35K
52 Week High
$26.74
52 Week Low
$11.00

Collections

Technology
Health
Biotechnology
Medical
Therapy
2016 IPO
Europe (Non-UK)
Europe

News

Seeking AlphaMar 11

IBI Research On Merus: Elucidating The Prospects Of An Antibody Innovator

I share with readers my forecasting of the aforementioned trial and what you can expect from this oncology-drug innovator. The lead molecule, MCLA-128, is most advanced in the pipeline. It has substantial prospects for the management of aggressive cancers. I remember my sense of shock some half-dozen years ago when I read a recommendation to sell shares of a company. The recommendation was not based on any long-term fundamentals. Rather, it was that over the next six months the funds could be employed mor...

13
MarketBeatMar 10

NASDAQ:MRUS - Stock Price, News, & Analysis for Merus

Headlines about MRUS stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 ou...

4

Earnings

-$1.33
-$0.96
-$0.60
-$0.23
Q1 2017
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.